EPRX

Eupraxia Pharmaceuticals Inc. NASDAQ Listed Apr 5, 2024

Healthcare ·Biotechnology ·CA · eupraxiapharma.com

$7.47

After hrs $7.45 +0.00%

Mkt Cap $250.1M

52w Low $3.67 67.3% of range 52w High $9.32

50d MA $7.39 200d MA $6.69

P/E (TTM) -7.5x

EV/EBITDA -5.7x

P/B 3.9x

Debt/Equity 0.0x

ROE —

P/FCF -10.2x

RSI (14) —

ATR (14) —

Beta 1.42

50d MA $7.39

200d MA $6.69

Avg Volume 224.8K

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

SIC Code

2834

CIK (SEC)

1581178

Phone

250 590 3968

2067 Cadboro Bay Road · Victoria, BC V8R 5G4 · CA

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 12, 2026	AMC	-0.16	-0.37	-131.2%	7.50	-0.5%	-1.9%	-1.5%	+1.1%	+0.1%	+1.3%	—
Nov 4, 2025	AMC	-0.23	-0.19	+17.4%	5.45	+0.0%	+4.0%	+2.4%	+0.0%	+14.3%	+19.8%	—
Aug 12, 2025	AMC	-0.21	-0.26	-23.8%	5.37	+2.6%	+1.5%	-1.7%	-0.9%	-1.3%	+0.4%	—
May 6, 2025	AMC	-0.19	-0.21	-10.5%	4.06	-5.2%	-6.7%	-6.4%	-6.4%	-7.4%	-4.7%	—
Mar 20, 2025	AMC	-0.18	-0.21	-16.7%	3.91	+1.0%	-2.3%	-6.9%	-9.5%	-13.6%	-13.6%	—
Nov 7, 2024	AMC	-0.13	-0.17	-30.1%	3.16	+0.9%	+1.6%	-4.7%	-8.2%	-10.1%	-8.2%	—
Aug 7, 2024	AMC	-0.17	-0.17	-0.4%	2.39	+1.7%	+5.4%	+12.1%	+13.8%	+4.2%	+9.2%	—
May 8, 2024	AMC	-0.17	-0.21	-23.2%	2.90	+1.0%	+1.0%	+0.0%	+0.0%	+1.7%	+2.8%	—
Mar 21, 2024	AMC	—	-0.15	—	—	—	—	—	—	—	—	—
Sep 30, 2023	AMC	-0.11	-0.25	-124.1%	—	—	—	—	—	—	—	—
Jun 30, 2023	AMC	-0.27	-0.36	-31.0%	—	—	—	—	—	—	—	—
Mar 31, 2023	AMC	-0.17	-0.23	-34.4%	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.02	$7.08	+0.9%	+0.6%	+3.3%	+2.0%	+2.7%	+1.3%
Mar 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.39	$7.36	-0.4%	+2.6%	+1.6%	+2.8%	-3.9%	-0.8%
Jan 15	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$8.43	$8.56	+1.5%	+4.0%	+3.8%	+7.0%	+7.1%	+6.9%
Jan 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.59	$8.52	-0.8%	-5.5%	-4.5%	-3.3%	-1.9%	+2.1%
Aug 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.39	$5.46	+1.3%	-1.7%	-3.3%	-2.0%	-3.0%	-6.3%

Data updated apr 25, 2026 7:26am · Source: massive.com